JD Byram

Regional Clinical Advisor /ACE Trainer/Pro Team and P-Club winner

[JD Byram @jdbyram]

@WilliamTateBook SORA 2

[JD Byram @jdbyram]

@auhazar SORA 2

[BostonSci Cardiology @BSCCardiology]

The FDA has officially approved new WATCHMAN FLX™ Pro #LAAC Device IFU label updates! The label updates include:
✅A new indication for NVAF patients post-catheter ablation
✅A new 45-day NOAC alone (followed by DAPT) post-implant drug regimen option for standalone LAAC patientThe FDA has officially approved new WATCHMAN FLX™ Pro #LAAC Device IFU label updates! The label updates include:
✅A new indication for NVAF patients post-catheter ablation
✅A new 45-day NOAC alone (followed by DAPT) post-implant drug regimen option for standalone LAAC patientThe FDA has officially approved new WATCHMAN FLX™ Pro #LAAC Device IFU label updates! The label updates include:
✅A new indication for NVAF patients post-catheter ablation
✅A new 45-day NOAC alone (followed by DAPT) post-implant drug regimen option for standalone LAAC patientThe FDA has officially approved new WATCHMAN FLX™ Pro #LAAC Device IFU label updates! The label updates include:
✅A new indication for NVAF patients post-catheter ablation
✅A new 45-day NOAC alone (followed by DAPT) post-implant drug regimen option for standalone LAAC patients

[BostonSci Cardiology @BSCCardiology]

Expanding what’s possible for #AFib patients! The FARAPULSE™ PFA Platform is now approved for pulmonary vein isolation (PVI) and posterior wall ablation (PWA) in patients with drug-refractory, symptomatic persistent atrial fibrillation.

Learn more about FARAPULSE™ and the supporting clinical evidence: https://t.co/gtLrC2X4G3

FARAPULSE™ Pulsed Field Ablation System Indications, Safety, and Warnings: https://t.co/A64fZE9GVn

#PulsedFieldAblation #PFA #Epeeps

[BostonSci Cardiology @BSCCardiology]

Do your AFib patients want to stop OACs after getting an ablation? Doug Gibson, MD discusses the advantages of combining the WATCHMAN FLX™ Pro #LAAC Device with FARAPULSE™ #PFA Platform for AF ablation, highlighting the duration of anticoagulation for patients with excessive bleeding risk in the latest TransformAF: Concomitant Ablate & Close webinar series.

➡️ Watch now: https://t.co/NOZNgNmFaO

#EPeeps #AFib

[JD Byram @jdbyram]

@MikeMoustakass is loose in the K

[BostonSci Cardiology @BSCCardiology]

Watch how the WATCHMAN TruSteer™ Access System enabled @DrTomWaggoner to treat this heavily pectinated appendage with a WATCHMAN FLX™ Pro #LAAC Device:

· Placed the distal end of the device in the anterior space
· Mid-deploy steering to keep the device shoulders coaxial
· Additional steering to remove wire bias for closing the gap and a smooth release

IFU: https://t.co/NYBavYc9Tr

[JD Byram @jdbyram]

@dkenigsberg @BSCCardiology Flxcellent way to go!

[David Kenigsberg, MD @dkenigsberg]

Used a 40mm @BSCCardiology #Watchman Flex Pro #LAAO device to close a large LAA in a >7 foot tall patient this am; great outcome for the patient.
#EPeeps

[BostonSci Cardiology @BSCCardiology]

Discover the latest clinical data on the treatment of persistent AF using the FARAPULSE™ Pulsed Field Ablation System. Register to hear leading physicians, Dr. Vivek Reddy, Dr. Edward Gerstenfield, and Dr. Walid Saliba discuss new clinical data from the ADVANTAGE AF Trial. https://t.co/TWWmC8js3a
#PFA
@VivekReddyMD @epsmd

[BostonSci Cardiology @BSCCardiology]

Mark your calendars for more Late-Breaking Clinical Science from the OPTION Clinical Trial – coming to #HRS2025 on Friday, April 25th at 12:30 PM PDT.

💡Tune in for insights on the impact of #Afib recurrence on outcomes after left atrial appendage closure with the WATCHMAN FLX™ #LAAC Device in patients undergoing an atrial fibrillation ablation.

Review our full schedule of clinical data here: https://t.co/yTURPdsSrJ

[BostonSci Cardiology @BSCCardiology]

The next webinar in the Concomitant Ablate & Close Workflow Series is here!

Devi Nair, MD and Christopher Ellis, MD explore the transformative potential of the FARAPULSE™ Pulsed Field Ablation System and WATCHMAN FLX™ Pro #LAAC Device in real-world clinical scenarios, highlighting effective workflows and strategic treatment planning.

Join live on April 17th at 7–8pm EDT. We can't wait to see you! 👉 https://t.co/0Zd2X7ksOo

#EPeeps #PFA @Drdevignair @cellisvandyep

[JD Byram @jdbyram]

@ATVIAssist I just prestiged and at level 7 my loadouts are setup in menu but when I get into games it defaults to xm4 and it’s the same on all loadouts even if I change the weapons it’s shows on the loadout screen but when I return the the game it switches back to xm4.

[JD Byram @jdbyram]

@Royals Bobby maybe #2 on this list but he’s #1 in the hearts of Royals Fans!

[MLB @MLB]

These guys need no introduction 👑

[MLB @MLB]

These guys need no introduction 👑

[JD Byram @jdbyram]

FLXCELLENT news worth celebrating—The Watchman is marking 10 years since FDA approval! Over 500,000 people have swapped blood thinners for this life-changing device and proudly said #byebyebloodthinner. It’s amazing to see a decade of innovation in action, giving folks freedom from daily pills and peace of mind. Hats off to the teams and patients who’ve made this milestone epic.

[BostonSci Cardiology @BSCCardiology]

The first-ever FARAFLEX™ Mapping and Pulsed Field Ablation (PFA) Catheter case was completed at KBC Split in Split, Croatia as part of the premarket ELEVATE-PF feasibility study performed by Dr. Anic and observed by Drs. Wazni and Saliba.

Our innovation and clinical investment in FARAFLEX continue to position Boston Scientific as a leader in #PFA to further the treatment of cardiac arrhythmias.

Learn more about FARAPULSE Pulsed Field Ablation System: https://t.co/6XhIwkXuUK #EPeeps #PFA

[Rajesh Kabra @rajeshkabramd]

Congratulations ⁦@VivekReddyMD⁩ for receiving John Madden foundation award at #ISLAA2025; a well deserved recognition for your pioneering contributions in EP and Cardiology! ⁦@DJ_Lakkireddy⁩ ⁦@Drdevignair⁩ ⁦@LuigiDiBiaseMD⁩ ⁦⁦⁦@HRSonline⁩ #EPeeps

[BostonSci Cardiology @BSCCardiology]

See our latest #PFA trial results presented at #AFSymposium25:
ADVANTAGE AF US IDE Clinical Trial primary safety and effectiveness endpoints were met for treating patients with persistent atrial fibrillation (#PersAF).

▪️ At 12 months, the primary safety event rate was 2.3% [5.1% UCL] which met the 12.0% performance goal, with no reported stroke, PV stenosis, esophageal fistula or major access complications.

▪️ At 12 months, the primary effectiveness rate was 63.5% [57.3% LCL] which met the acceptance criteria of 40.0%. The rate of patients free from documented symptomatic recurrence was 85.3%, which improved to 91.8% when operators performed three or more trial procedures.

View the full trial results: https://t.co/OixSUPJQfV

#Epeeps

[BostonSci Cardiology @BSCCardiology]

PRIMARY ENDPOINTS MET! We are excited to announce the positive results from OPTION Clinical Trial – the primary endpoints showed WATCHMAN FLX™ was equally effective to OACs, with a superior safety profile at 36 months, which allowed patients to eliminate continuous medication use and significantly reduce bleeding risk while maintaining stroke protection. #AHA24

View the results here: https://t.co/VIPvCiKGy9

Safety info: https://t.co/NYBavYc9Tr

#AHA2024 #LAAC